<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04139772</url>
  </required_header>
  <id_info>
    <org_study_id>Meet-Uro4</org_study_id>
    <nct_id>NCT04139772</nct_id>
  </id_info>
  <brief_title>Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.</brief_title>
  <official_title>A Randomized Multicenter Phase III Trial Comparing Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase 3 trial aiming to compare the efficacy of docetaxel and hormone&#xD;
      therapy as second line treatment in patients with mCRPC progressing after therapy with&#xD;
      abiraterone or enzalutamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized 1:1 to receive docetaxel or hormone therapy (abiraterone or&#xD;
      enzalutamide based on previous treatment).&#xD;
&#xD;
      Docetaxel (standard) will be administered for 10 cycles (maximum).&#xD;
&#xD;
      Hormone therapy (experimental) will be administered until progression or unacceptable&#xD;
      toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment Comparative Randomized Phase 3 Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>OS is defined as the time from randomization until death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>PFS is defined as the time elapsed from the date of randomization to the date of progression, as defined by investigators, or the date of death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate-Specific Antigen (PSA) Progression</measure>
    <time_frame>up to 5 years</time_frame>
    <description>as determined by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic skeletal events (SSE)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>reporting the incidence and types of skeletal related events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptomatic skeletal event (SSE)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time from the date of randomization to the date of documented symptomatic skeletal event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Progression</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time from the date of randomization to the date of pain progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0</measure>
    <time_frame>baseline, during treatment (every 4 weeks) up to 5 years</time_frame>
    <description>graded according to Common Terminology Criteria for Adverse Event (CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of changes in quality of life</measure>
    <time_frame>baseline, during treatment up to 5 years</time_frame>
    <description>EORTC QLQ-C30, a quality of life questionnaires, composed by 30 items graded from1 (not at all) to 4 (very much) after 1 year from the diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response (bone lesions)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response (soft tissue lesions)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Prostate Cancer Working Group 3 (PCWG3) criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Metastatic Castration-resistent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone or Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive Abiraterone or Enzalutamide based on previous treatment.&#xD;
Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.&#xD;
Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate or Enzalutamide</intervention_name>
    <description>Patient will receive Abiraterone or Enzalutamide based on previous treatment.&#xD;
Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.&#xD;
Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.</description>
    <arm_group_label>Abiraterone or Enzalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Distant metastatic disease&#xD;
&#xD;
          -  Previous first line treatment with abiraterone or enzalutamide for 6 cycles&#xD;
             interrupted at least 2 weeks before randomization&#xD;
&#xD;
          -  Patients must be â‰¥ 18 years of age&#xD;
&#xD;
          -  Patients must have castrate serum level of testosterone of &lt; 0.5 ng/mL ( 1.7 nmol/L)&#xD;
&#xD;
          -  Asymptomatic or Oligosymptomatic disease&#xD;
&#xD;
          -  Progressive disease according to Prostate Cancer Clinical Trials Working Group 3&#xD;
             (PCWG3) criteria&#xD;
&#xD;
          -  ECOG performance status (PS) of 0-2&#xD;
&#xD;
          -  Sexually active males must use an accepted and effective method birth control measure&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to docetaxel or abiraterone for treatment of hormone-sensitive&#xD;
             metastatic prostate cancer (mHSPC)&#xD;
&#xD;
          -  History of adrenal insufficiency or hypoaldosteronism&#xD;
&#xD;
          -  Any medical condition that would make prednisone use contraindicated&#xD;
&#xD;
          -  Any medical condition that would make docetaxel use contraindicated&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication&#xD;
&#xD;
          -  Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV) requiring antiretroviral therapy&#xD;
&#xD;
          -  Other malignancy within the last 5 years, except for adequately treated non melanoma&#xD;
             skin cancer, bladder cancer (pTis, pTa, pT1) or other solid tumours curatively treated&#xD;
             with no evidence of disease for &gt; 5 years&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product within 30 days&#xD;
             prior to randomization&#xD;
&#xD;
          -  Persistent toxicities [&gt;Common Terminology Criteria for Adverse Event (CTCAE) grade&#xD;
             1)] caused by previous cancer therapy prior to randomization&#xD;
&#xD;
          -  Uncontrolled medical conditions including diabetes mellitus. Clinically significant&#xD;
             cardiovascular disease (e.g.: uncontrolled hypertension or arrhythmia, unstable angina&#xD;
             pectoris, congestive heart failure (CHF), vascular disease (arterial thrombosis) and&#xD;
             myocardial infarction within &lt; 6 months&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
          -  Peripheral neuropathy [&gt; CTCAE grade 2]&#xD;
&#xD;
          -  Inadequate bone marrow function defined as:&#xD;
&#xD;
               -  haemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
               -  absolute neutrophils count (ANC) &lt;1.5 x 109/L (&gt; 1500 per mm3)&#xD;
&#xD;
               -  platelet count &lt;100 x 109/L (&gt;100,000 per mm3)&#xD;
&#xD;
          -  Inadequate renal and hepatic function, defined as:&#xD;
&#xD;
               -  total serum bilirubin &gt; 1,0 x ULN&#xD;
&#xD;
               -  AST/SGOT o ALT/SGPT &gt; 1,5 x ULN&#xD;
&#xD;
               -  calculated creatinine clearance &lt; 40 mL/min&#xD;
&#xD;
               -  potassium level &lt; 3,5 mmol/L&#xD;
&#xD;
               -  Child-Pugh class C&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients with metastatic castration resistent prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaetano Facchini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Orazio Caffo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Department, Ospedale Santa Chiara, Trento</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clorinda Schettino, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://usc-intnapoli.net</url>
    <description>sponsor web-site for study conduction</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic castration-resistent prostate cancer</keyword>
  <keyword>asymptomatic or oligosymptomatic</keyword>
  <keyword>hormone therapy</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

